ICU · Infection / oncology
Neutropenic Sepsis — The Golden Hour & the Antipseudomonal Beta-Lactam
Also known as Neutropenic sepsis · Febrile neutropenia · Neutropenic fever · Chemotherapy sepsis · Golden hour · Mucositis translocation · MASCC risk index · CISNE index · Piperacillin-tazobactam · Ceftazidime · Cefepime · Meropenem · G-CSF · Echinocandin · Liposomal amphotericin B · Viridans streptococcal shock syndrome · Invasive pulmonary aspergillosis · Typhlitis · Differential time to positivity
Febrile neutropenia: treat swiftly and broadly (Freifeld). ASCO/IDSA: initial empirical antibacterials within 1 hour of triage. SSC 2021: antimicrobials immediately, ideally within 1 h for possible shock; ≥30 mL/kg crystalloid within 3 h — not an Hour-1 all-five checkbox. Empiric anti-pseudomonal beta-lactam (Bow: pip-taz 4.5 g q6h or cefepime 2 g q8h in 528 high-risk patients). Walsh: caspofungin 33.9% vs L-AmB 33.7%. G-CSF is prophylaxis (Kuderer FN RR 0.54; ASCO ~20%). Numeric IDSA fever/ANC cut-offs are not quoted from the fetched Freifeld abstract.
Checked against its sources on 3 Sept 2026
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
CICMFFICMEDIC
Red flags
- ASCO/IDSA: initial empirical antibacterials within 1 hour of triage. SSC 2021: ideally 1 h for possible shock. Not an Hour-1 all-five checkbox.
- Treat fever and neutropenia swiftly and broadly (Freifeld). Numeric ANC/fever cut-offs are not quoted from the fetched Freifeld abstract.
- NEVER ceftriaxone as the sole empiric — no anti-pseudomonal activity.
- Cultures from each central-line lumen plus peripheral if this causes no substantial delay.
- Persistent fever: hunt fungus (Walsh empirical caspofungin 33.9% vs L-AmB 33.7%). A 4–7 day clock is not in the fetched Walsh abstract.
- G-CSF is prophylaxis (Kuderer FN RR 0.54; ASCO ~20% FN-risk regimens), not the shock drug.
- Mucormycosis — galactomannan not a mucor test; first-line high-dose L-AmB plus surgery (Cornely/Lewis).
[1]
[2]
[4]
[14]
[16]
[8]
[11]
[2]
[16]
[8]
[32]
[31]
[1]
[2]
[14]
[13]
Febrile neutropenia — sourced numbers
1 hTriage to first antibioticTaplitz/Flowers ASCO/IDSA
4.5 g q6hPip-taz (Bow trial)vs cefepime 2 g q8h, n=528
33.9 vs 33.7%Walsh overall successcaspofungin vs L-AmB
PPV 91%MASCC ≥21Klastersky derivation n=756
Meet the patient
A 47-year-old man, day 10 of 7+3 induction for newly diagnosed AML, arrives with grade 3 oral mucositis, rigors, fever 39.5, confusion, and dyspnoea. Neutrophils 0.08, platelets 19, lactate 5.2, MAP 49, bilateral infiltrates on the chest X-ray, SpO2 88 per cent on room air. He has a tunnelled central line and is on levofloxacin prophylaxis.[1]
Two clocks are running against him. The first is the Pseudomonas clock — this neutropenic host has no neutrophil buffer, and Pseudomonas aeruginosa can kill within hours. The second is the ARDS clock from viridans streptococcal shock. The cultures are still being drawn, and the answer to "should I wait for them" is the answer to every neutropenic-sepsis stem: no — give the antipseudomonal beta-lactam now, within the hour, and let the cultures guide the de-escalation later.[1]
References32ShowHide
- [1]Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america Clin Infect Dis, 2011.PMID 21258094
- [2]Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update J Clin Oncol, 2018.PMID 29461916
- [3]Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients Support Care Cancer, 2013.PMID 23443617
- [4]Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline J Clin Oncol, 2013.PMID 23319691
- [5]Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America Clin Infect Dis, 2016.PMID 27365388
- [6]Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America Clin Infect Dis, 2016.PMID 26679628
- [7]Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med, 2002.PMID 12167683
- [8]Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia N Engl J Med, 2004.PMID 15459300
- [9]Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update J Clin Oncol, 2015.PMID 26169616
- [10]Bohlius J, Herbst C, Reiser M, et al. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma Cochrane Database Syst Rev, 2008.PMID 18843642
- [11]Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review J Clin Oncol, 2007.PMID 17634496
- [12]Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study J Clin Oncol, 2015.PMID 25559804
- [13]Seymour CW, Gesten F, Prescott HC, et al. Time to Treatment and Mortality during Mandated Emergency Care for Sepsis N Engl J Med, 2017.PMID 28528569
- [14]Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 Intensive Care Med, 2021.PMID 34599691
- [15]De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock N Engl J Med, 2010.PMID 20200382
- [16]Bow EJ, Rotstein C, Noskin GA, et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies Clin Infect Dis, 2006.PMID 16838234
- [17]de la Cámara R, Figuera A, Sureda A, et al. Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study Haematologica, 1997.PMID 9580087
- [18]Harris PNA, Tambyah PA, Lye DC, et al. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial JAMA, 2018.PMID 30208454
- [19]Andreatos N, Flokas ME, Apostolopoulou A, et al. The Dose-Dependent Efficacy of Cefepime in the Empiric Management of Febrile Neutropenia: A Systematic Review and Meta-Analysis Open Forum Infect Dis, 2017.PMID 28761897
- [20]Baltas I, Hederih J, Kvam N, et al. Ciprofloxacin prophylaxis in allogeneic haematopoietic cell transplantation reduces bacteraemia but increases antimicrobial resistance without improving patient outcomes Int J Infect Dis, 2026.PMID 41916493
- [21]Kullberg BJ, Viscoli C, Pappas PG, et al. Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial Clin Infect Dis, 2019.PMID 30289478
- [22]Shorr AF, Wu C, Kothari S Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei J Antimicrob Chemother, 2011.PMID 21147825
- [23]Yamashita C, Takesue Y, Matsumoto K, et al. Echinocandins versus non-echinocandins for empirical antifungal therapy in patients with hematological disease with febrile neutropenia: A systematic review and meta-analysis J Infect Chemother, 2020.PMID 32171659
- [24]Hanai Y, Hamada Y, Kimura T, et al. Favorable Effects of Voriconazole Trough Concentrations Exceeding 1 µg/mL on Treatment Success and All-Cause Mortality: A Systematic Review and Meta-Analysis J Fungi (Basel), 2021.PMID 33923727
- [25]Takesue Y, Hanai Y, Oda K, et al. Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring Clin Ther, 2022.PMID 36424314
- [26]Lewis RE, Kontoyiannis DP Does the Evidence Support High-Dose Liposomal Amphotericin B in the Treatment of Mucormycosis? J Infect Dis, 2026.PMID 42479449
- [27]Danion F, Aguilar C, Catherinot E, et al. Mucormycosis: New Developments into a Persistently Devastating Infection Semin Respir Crit Care Med, 2015.PMID 26398536
- [28]Laporte-Amargos J, Gudiol C, Arnan M, et al. Efficacy of extended infusion of beta-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE) Trials, 2020.PMID 32423462
- [29]Coussement J, Lindsay J, Teh BW, et al. Choice and duration of antifungal prophylaxis and treatment in high-risk haematology patients Curr Opin Infect Dis, 2021.PMID 34039878
- [30]Bouteloup M, Perinel S, Bourmaud A, et al. Outcomes in adult critically ill cancer patients with and without neutropenia: a systematic review and meta-analysis of the Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologie (GRRR-OH) Oncotarget, 2017.PMID 27661125
- [31]Nates JL, Pène F, Darmon M, et al. Septic shock in the immunocompromised cancer patient: a narrative review Crit Care, 2024.PMID 39215292
- [32]Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients J Clin Oncol, 2000.PMID 10944139